KalVista Pharmaceuticals SEC filings document 8-K disclosures for a commercial-stage pharmaceutical company focused on oral rare-disease therapies. The filings cover results of operations and financial condition, Regulation FD materials, product-revenue updates tied to EKTERLY, and the company’s Nasdaq-listed common stock.
The filing record also includes governance and compensation disclosures, board committee changes, executive appointments, material definitive agreements, and capital-structure actions. Financing disclosures include the completed sale of 3.250% convertible senior notes due 2031, while other reports describe exhibit filings, furnished press releases, Inline XBRL cover data, and formal disclosure treatment under the Exchange Act.
KalVista Pharmaceuticals reported an equity award for its Chief Financial Officer, Brian Piekos. On January 16, 2026, he received 100,000 restricted stock units (RSUs), each representing the right to receive one share of KalVista common stock for no cash consideration upon settlement.
The RSUs are scheduled to vest in equal installments, with 1/16 of the total vesting on each quarterly anniversary of the vesting commencement date starting on May 22, 2026, as long as his service with the company continues. Following this grant, he beneficially owns 100,000 derivative securities in the form of RSUs, held directly.
KalVista Pharmaceuticals’ chief medical officer receives new equity award. Paul K. Audhya, the company’s Chief Medical Officer, reported a grant of 100,000 restricted stock units on January 16, 2026. Each RSU represents the right to receive 1 share of KalVista common stock upon settlement for no cash payment. The RSUs will vest over four years, with 1/16 of the total units vesting on each quarterly anniversary of the vesting commencement date, starting on May 22, 2026, as long as his service with the company continues. Following this grant, he beneficially owns 100,000 derivative securities directly.
KalVista Pharmaceuticals, Inc. reported that its Chief Executive Officer and director, Benjamin L. Palleiko, received a grant of 325,000 restricted stock units (RSUs) on January 16, 2026. Each RSU represents a contingent right to receive one share of KalVista common stock for no cash consideration when the units settle.
According to the vesting terms, 1/16 of the RSUs will vest on each quarterly anniversary of the vesting commencement date, starting on May 22, 2026, as long as his service with the company does not terminate. Following this award, Palleiko directly holds 325,000 derivative securities in the form of RSUs.
KalVista Pharmaceuticals, Inc. received an updated ownership disclosure from Point72-related entities and Steven A. Cohen, who report beneficial ownership of 2,781,902 shares of common stock, representing 5.5% of the company. The shares are held by Point72 Associates, LLC, with investment and voting power managed by Point72 Asset Management, L.P., whose general partner is Point72 Capital Advisors, Inc., all controlled by Mr. Cohen.
This filing is Amendment No. 1 to a prior Schedule 13G and is made to correct the beneficial ownership previously disclosed. The reporting persons state that the securities are not held for the purpose of changing or influencing control of KalVista Pharmaceuticals.
KalVista Pharmaceuticals, Inc. disclosed that investment entities associated with Point72 Asset Management, L.P., including Point72 Capital Advisors, Inc. and Steven A. Cohen, beneficially own 2,523,493 shares of its common stock. This position represents 4.9% of the outstanding common stock as of the close of business on January 9, 2026. The shares are held by an investment fund managed by Point72 Asset Management, which has shared voting and dispositive power over the position.
The reporting persons state that the securities were not acquired for the purpose of changing or influencing control of KalVista and are reported on a passive Schedule 13G basis. Each of Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen disclaims being the beneficial owner of the shares for certain legal purposes, even though they may be deemed to share investment and voting power under the securities laws.
KalVista Pharmaceuticals reported preliminary global net revenue of approximately $35 million for the quarter and $49 million for the eight‑month transition period ended December 31, 2025. These figures are early estimates and rely on the company’s financial closing procedures and the completion of an audit of its financial statements for that transition period. The company emphasized that the final audited results could differ materially from these preliminary numbers. KalVista also released a press release and an updated corporate presentation, which are attached as exhibits to this report.
KalVista Pharmaceuticals (KALV) reported an insider equity transaction by its Chief Development Officer. On 11/20/2025, the officer exercised an employee stock option to acquire 87,390 shares of common stock at an exercise price of $0.0043 per share, coded as transaction type "M" (option exercise). After this transaction, the officer directly beneficially owned 220,964 shares of KalVista common stock. The related employee stock option, which was 100% vested, was fully exercised and no derivative securities remained beneficially owned.
KalVista Pharmaceuticals, Inc. insider activity: the company’s Chief Executive Officer and director reported routine equity award activity. On 11/17/2025, the reporting person acquired 9,364 shares of common stock through the vesting and settlement of restricted stock units (coded “M”), increasing directly held common shares to 408,345. On 11/18/2025, 4,466 shares of common stock were sold at a weighted average price of $14.4794 per share, leaving 403,879 shares of common stock directly owned.
The sale was made to cover tax withholding obligations arising from RSU vesting under a “sell to cover” arrangement and is described as non-discretionary. Related RSU awards provided common shares at no cash exercise price, with portions vesting in equal installments on quarterly anniversaries of their respective vesting commencement dates, subject to continued service.
KalVista Pharmaceuticals, Inc. insider trading report: The company’s Chief Development Officer filed a Form 4 detailing routine equity award activity. On 11/17/2025, the officer acquired 4,205 shares of KalVista common stock following the vesting and settlement of restricted stock units (RSUs), which convert to common stock on a one-for-one basis for no cash consideration. On 11/18/2025, 2,683 shares were sold in a broker-assisted “sell to cover” transaction at a weighted average price of $14.4794 per share to satisfy tax withholding obligations tied to the RSU vesting, described as non-discretionary. After these transactions, the officer beneficially owned 133,574 shares of KalVista common stock, held directly.
KalVista Pharmaceuticals' (KALV) Chief Medical Officer reported equity activity involving restricted stock units and related share sales. On 11/17/2025, 6,447 shares of common stock were acquired through the vesting and settlement of restricted stock units, increasing direct holdings to 128,952 shares. On 11/18/2025, 3,075 shares were sold at a weighted average price of $14.4795 per share to cover tax withholding obligations from the RSU vesting, a non-discretionary "sell to cover" transaction, leaving 125,877 shares directly owned.
The filing also shows RSU awards converting into 2,419 and 4,028 shares of common stock at a conversion price of $0 per RSU. One RSU grant vests in 1/16th increments each quarterly anniversary of its vesting commencement date, and another in 1/12th quarterly increments, in each case conditioned on continued service.